Head to Head Review: Haemonetics (NYSE:HAE) vs. TearLab (NYSE:TEAR)

Haemonetics (NYSE:HAE) and TearLab (OTCMKTS:TEAR) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, profitability, dividends, risk and institutional ownership.

Analyst Ratings

This is a breakdown of recent recommendations for Haemonetics and TearLab, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Haemonetics 0 0 5 0 3.00
TearLab 0 0 0 0 N/A



Haemonetics presently has a consensus target price of $144.40, indicating a potential upside of 12.56%. Given Haemonetics’ higher possible upside, research analysts clearly believe Haemonetics is more favorable than TearLab.

Risk and Volatility

Haemonetics has a beta of 0.81, indicating that its share price is 19% less volatile than the S&P 500. Comparatively, TearLab has a beta of 0.93, indicating that its share price is 7% less volatile than the S&P 500.

Profitability

This table compares Haemonetics and TearLab’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Haemonetics 5.05% 21.07% 10.91%
TearLab -13.60% N/A -21.58%

Insider and Institutional Ownership

99.0% of Haemonetics shares are held by institutional investors. 1.3% of Haemonetics shares are held by insiders. Comparatively, 5.2% of TearLab shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Haemonetics and TearLab’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Haemonetics $967.58 million 6.73 $55.02 million $2.39 53.68
TearLab $25.00 million 0.03 -$2.25 million N/A N/A

Haemonetics has higher revenue and earnings than TearLab.

Summary

Haemonetics beats TearLab on 9 of the 11 factors compared between the two stocks.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. The company also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx and El-Dorado Donor donation and blood unit management systems; Hemasphere software that provides support for blood drive planning; and Donor Doc and e-Donor software to enhance the donor recruitment and retention. In addition, it offers hospital products comprising TEG diagnostic systems that enables clinicians to assess the coagulation status of a patient at the point-of-care or laboratory setting; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; Cell Saver Elite +, a surgical blood salvage system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; OrthoPAT, a perioperative autotranfusion system for orthopedic procedures; and BloodTrack, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. Haemonetics Corporation was founded in 1971 and is headquartered in Braintree, Massachusetts.

TearLab Company Profile

TearLab Corporation operates as an in-vitro diagnostic company in the United States and internationally. It offers TearLab Osmolority System, a proprietary in vitro diagnostic tear testing platform that measures tear film osmolarity for the diagnosis of dry eye disease; and enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. Its TearLab Osmolarity System consists of TearLab disposable, a single-use microfluidic microchip; TearLab pen, a hand-held device that interfaces with the TearLab disposable; and TearLab reader, a small desktop unit that allows for the docking of the TearLab pen, as well as provides a quantitative reading for the operator. The company was formerly known as OccuLogix, Inc. TearLab Corporation was founded in 1996 and is headquartered in San Diego, California.

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.